PMC:7161517 / 414-587 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":4,"end":12},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"CE2 activity was shown to mediate disease protection. Because angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 rece"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":62,"end":76},"obj":"Chemical"},{"id":"T7","span":{"begin":62,"end":73},"obj":"Chemical"},{"id":"T8","span":{"begin":74,"end":76},"obj":"Chemical"},{"id":"T9","span":{"begin":96,"end":110},"obj":"Chemical"},{"id":"T10","span":{"begin":100,"end":110},"obj":"Chemical"},{"id":"T11","span":{"begin":116,"end":133},"obj":"Chemical"},{"id":"T12","span":{"begin":143,"end":154},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"},{"id":"A5","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_48432"},{"id":"A6","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_58506"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_25354"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"}],"text":"CE2 activity was shown to mediate disease protection. Because angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 rece"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T15","span":{"begin":62,"end":76},"obj":"DG_37;PR:000001118"},{"id":"T16","span":{"begin":77,"end":85},"obj":"PR:000001118"},{"id":"T17","span":{"begin":100,"end":110},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T18","span":{"begin":116,"end":133},"obj":"CHEBI:25354;CHEBI:25354"},{"id":"T19","span":{"begin":134,"end":154},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T20","span":{"begin":164,"end":168},"obj":"PR:000003622;G_3;PG_10"},{"id":"T39187","span":{"begin":62,"end":76},"obj":"DG_37;PR:000001118"},{"id":"T33501","span":{"begin":77,"end":85},"obj":"PR:000001118"},{"id":"T28542","span":{"begin":100,"end":110},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T14634","span":{"begin":116,"end":133},"obj":"CHEBI:25354;CHEBI:25354"},{"id":"T38268","span":{"begin":134,"end":154},"obj":"CHEBI:48561;CHEBI:48561"},{"id":"T7996","span":{"begin":164,"end":168},"obj":"PR:000003622;G_3;PG_10"}],"text":"CE2 activity was shown to mediate disease protection. Because angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 rece"}

{"project":"LitCovid-PubTator","denotations":[{"id":"26","span":{"begin":96,"end":99},"obj":"Gene"},{"id":"27","span":{"begin":116,"end":142},"obj":"Gene"},{"id":"28","span":{"begin":164,"end":168},"obj":"Gene"}],"attributes":[{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"Gene:1636"},{"id":"A27","pred":"tao:has_database_id","subj":"27","obj":"Gene:4306"},{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"Gene:59272"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"CE2 activity was shown to mediate disease protection. Because angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists increase ACE2 rece"}